ArticleJournal of medicinal chemistry2026

From Discovery to Clinical Trial: YCT-529, an Oral NonHormonal Male Contraceptive Targeting the Retinoic Acid Receptor Alpha.

Rui Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.